Tesamorelin
Tesamorelin is a stabilized GHRH analogue (a synthetic form of GRF 1-44).
- Vial Size
- 20mg
- Molecular Weight
- 5135.85 g/mol
- Half-life
- ~26 minutes (plasma, research models)
- Latest Lot Purity
- 99.26%
Mechanism of Action
Tesamorelin is a stabilized GHRH analogue (a synthetic form of GRF 1-44). Studied for its capacity to drive endogenous GH pulses via the pituitary GHRH receptor in research models of visceral adiposity and metabolic dysregulation.
Research Context
- Visceral adipose tissue research
- Lipid and metabolic-profile studies
- GHRH-receptor pharmacology
- Endogenous GH pulsatility research
trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-... (44 aa)
Lot NX-019 · Verified at 99.26%
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for Tesamorelin.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the Tesamorelin monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 1–2 mg
- Frequency
- Once daily, evening
- Cycle Length
- 12–26 weeks
- Route
- Subcutaneous
Note ·Evening dosing aligns with endogenous GH pulse research.
Related Compounds
All compounds →
CJC 1295 (without DAC) + IPA
Dual-component GH-axis research blend.
HGH Fragment 176-191
Lipolytic GH fragment for body-composition research models.
Ipamorelin
Selective growth hormone secretagogue for protocol layering.
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.